THE European Medicines
Authority has fast-tracked
a recommendation for a
marketing authorisation for
Boehringer Ingelheim’s Praxbind
(idarucizumab) as a specific
antidote to the new generation
anticoagulant medicine Pradaxa
(dabigatran etexilate).
Praxbind is to be used when a
patient taking Pradaxa needs to
undergo an emergency surgery,
or when life-threatening or
uncontrolled bleeding occurs.The above article was sent to subscribers in Pharmacy Daily's issue from 28 Sep 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Sep 15
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.